Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy

Yi-Zi Zheng; Jia-Ying Li; Lv-Wen Ning; Ni Xie

doi:10.2147/BCTT.S387209

Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy

Breast Cancer (Dove Med Press). 2022 Dec 21:14:475-487. doi: 10.2147/BCTT.S387209. eCollection 2022.

Authors

Yi-Zi Zheng^#¹, Jia-Ying Li^#^{2

3}, Lv-Wen Ning³, Ni Xie³

Affiliations

¹ Department of Thyroid and Breast Surgery, Shenzhen Breast Tumor Research Center for Diagnosis and Treatment, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen University, Shenzhen, Guangdong, People's Republic of China.
² Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
³ Biobank, First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen University, Shenzhen, Guangdong, People's Republic of China.

^# Contributed equally.

Abstract

Introduction: Tripartite motif-containing protein (TRIM) family members play crucial roles in carcinogenesis and chemotherapy resistance. In this study, we aimed to determine whether TRIM58 protein expression is related to patient responses to neoadjuvant therapy (NAT) and their survival outcome.

Methods: Immunohistochemistry was performed on female breast cancer samples from biopsies before NAT in Shenzhen Second People's Hospital. Univariate and multivariate logistic regression tests were used to analyze the association between TRIM58 protein expression and pathological complete response (pCR). The Cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with a 95% confidence interval (95% CI). The Kaplan-Meier plotter database was used to analyze the prognostic value of TRIM58.

Results: High TRIM58 expression was associated with small tumor size in all the patients (n = 58). Multivariate analysis suggested that low TRIM58 expression was an independent predictive factor for higher pCR (odds ratio = 0.06, 95% CI 0.005-0.741, P = 0.028). The Kaplan-Meier Plotter dataset suggested that the TRIM58 high-expression group showed a worse 5-year overall survival than the low-expression group (HR = 1.34, 95% CI 1.07-1.67, P = 0.01). Pathway analysis revealed the potential mechanisms of TRIM58 in chemoresistance.

Discussion: Our study suggests that TRIM58 is a promising biomarker for both neoadjuvant chemosensitivity and long-term clinical outcomes in breast cancer. It may also help to identify candidate responders and determine treatment strategies.

Keywords: biomarker; chemosensitivity; pathological complete response; patient stratification; predictive diagnostics.

Grants and funding

This work was supported by the National Natural Science Foundation of China (Grant Number: 81902682, 82273397, 82172356, 81972003); Guangdong Basic and Applied Basic Research Foundation (Grant Number: 2021A1515011122, 2021A1515012144, 2020A1515111165); Shenzhen Science and Technology Project (Grant Number: JCYJ20210324103003010); Science, Technology and Innovation Commission of Shenzhen Municipality (Grant Number: JCYJ20180507182025817); Clinical Research Project of Shenzhen Second People’s Hospital (Grant Number: 20223357015).